Gilead Pharmasset LLC

Gilead Sciences, Inc.

Ashley Anne Katana

John O Link

Zheng-Yu Yang

Darryl Kato

Jeromy J Cottell

Teresa Alejandra Trejo Martin

Sheila M Zipfel

Elizabeth M Bacon

James G Taylor

Chinh Viet Tran

Evan S Krygowski

Jeff A Zablocki

Hyung-Jung Pyun

Adam James Schrier

Michael Sangi

Elbert Chin

Nathan D Shapiro

Dustin S Siegel

Barton W Phillips

Eda Y Canales

Tetsuya Kobayashi

Randall W Vivian

Ruben Martinez

Kapil Kumar Karki

Kyla Bjornson

William John Watkins

Kevin S Currie

Scott A Mitchell

Chandrasekar Venkataramani

Scott E Lazerwith

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Gregory Notte

Seung H Lee

Juan A Guerrero

Zhongdong Zhao

Aaron C Schmitt

Jiayao Li

Zhimin Du

Jayaraman Chandrasekhar

Kirk L Stevens

Jennifer R Lo

Julie Farand

Nicholas Mai

Jin-Ming Xiong

Kyla Ramey

JinMing Xiong

Dustin Siegel

Jeff Zablocki

James Taylor

Jeromy Cottell

Jinming Xiong

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

The invention provides a compound of Formula I:

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Antiviral compounds

Compounds of Formula I are disclosed  As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Inhibitors of hepatitis C virus

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Syk inhibitors

Substituted pyrrolidines as SYK inhibitors

Growing community of inventors

San Mateo, CA, United States of America

Ashley Anne Katana